DNA

4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer

Interim data to be presented in an oral presentation by Dr. Arshad M. Khanani, M.D., M.A., FASRS at the 2023…

1 year ago

High steady state of COVID-19 case levels are a concern, according to CoVaRR-Net experts

More booster shots and improved ventilation remain part of the answer to decrease COVID-19 casesOTTAWA, April 13, 2023 (GLOBE NEWSWIRE)…

1 year ago

Eminent Trauma Researcher Dr. Lipov and Author Jamie Mustard Release New Book to Introduce Revolutionary PTSD Treatment to the Masses

“The Invisible Machine” reveals the startling truth about trauma and the scientific breakthrough that could transform millions of lives The…

1 year ago

Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference

STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to…

1 year ago

Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference 

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people…

1 year ago

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress…

1 year ago

Mainz Biomed Provides Full Year 2022 Financial Results

ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, Calif. and MAINZ, Germany, April…

1 year ago

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

Poster Presentations to highlight the latest research on OBI-999’s (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and…

1 year ago

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”),…

1 year ago

Ocean Biomedical (NASDAQ: OCEA) Will Target Pulmonary Fibrosis Discoveries as Novel Treatments of Hermansky-Pudlak Syndrome

On Hermansky-Pudlak Syndrome (HPS) Awareness Day, Ocean Biomedical announces a commitment to developing viable treatment options for HPS-1 and HPS-4…

1 year ago